Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) – Pipeline Review, H2 2017’, provides in depth analysis on Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Metabolic Disorders, Gastrointestinal, Immunology and Undisclosed under development targeting Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20)

The report reviews Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics and enlists all their major and minor projects

The report assesses Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

GlaxoSmithKline Plc

Merck & Co Inc

Viking Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC

2.3.1.76 or EC

2.3.1.20) - Overview 5

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC

2.3.1.76 or EC

2.3.1.20) - Therapeutics Development 6

Products under Development by Stage of Development 6

Products under Development by Therapy Area 7

Products under Development by Indication 8

Products under Development by Companies 9

Products under Development by Universities/Institutes 11

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC

2.3.1.76 or EC

2.3.1.20) - Therapeutics Assessment 13

Assessment by Mechanism of Action 13

Assessment by Route of Administration 14

Assessment by Molecule Type 15

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC

2.3.1.76 or EC

2.3.1.20) - Companies Involved in Therapeutics Development 16

GlaxoSmithKline Plc 16

Merck & Co Inc 16

Viking Therapeutics Inc 17

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC

2.3.1.76 or EC

2.3.1.20) - Drug Profiles 18

GSK-3008356 - Drug Profile 18

Product Description 18

Mechanism Of Action 18

R&D Progress 18

KR-69530 - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

Small Molecule to Inhibit DGAT1 for Hyperlipidemia - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

Small Molecules to Inhibit DGAT-1 for Inflammation and Metabolic Disorders - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

Small Molecules to Inhibit DGAT1 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC

2.3.1.76 or EC

2.3.1.20) - Dormant Products 23

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC

2.3.1.76 or EC

2.3.1.20) - Discontinued Products 25

Appendix 26

Methodology 26

Coverage 26

Secondary Research 26

Primary Research 26

Expert Panel Validation 26

Contact Us 26

Disclaimer 27

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 6

Number of Products under Development by Therapy Areas, H2 2017 7

Number of Products under Development by Indication, H2 2017 8

Number of Products under Development by Companies, H2 2017 9

Products under Development by Companies, H2 2017 10

Number of Products under Investigation by Universities/Institutes, H2 2017 11

Products under Investigation by Universities/Institutes, H2 2017 12

Number of Products by Stage and Mechanism of Actions, H2 2017 13

Number of Products by Stage and Route of Administration, H2 2017 14

Number of Products by Stage and Molecule Type, H2 2017 15

Pipeline by GlaxoSmithKline Plc, H2 2017 16

Pipeline by Merck & Co Inc, H2 2017 17

Pipeline by Viking Therapeutics Inc, H2 2017 17

Dormant Products, H2 2017 23

Dormant Products, H2 2017 (Contd..1), H2 2017 24

Discontinued Products, H2 2017 25

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 6

Number of Products under Development by Therapy Areas, H2 2017 7

Number of Products under Development by Indications, H2 2017 8

Number of Products by Stage and Mechanism of Actions, H2 2017 13

Number of Products by Stage and Route of Administrations, H2 2017 14

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports